Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl

#OP0251 #EULAR2022 Any data to support association of RA-ILD with poor #COVID outcomes? A study is US >500 pts (9% ILD) showed ILD as well as poor RA status (RF+ & erosion) increased risk. Detailed analysis inc Radiographic + PFT cd help stratify risk further @RheumNow https://t.co/E89dd38GQS

#EULAR2022 OP0276: What do patients want for preventative interventions for RA? ⭐️Survey of 1st degree relatives of RA pts (at risk) vs general pop were similar ⭐️'Hypothetical' treatment profile best aligned to abatacept @Rheumnow https://t.co/r4y7SZbjTA

Montastruc et al. VigiBase study of CV and VTE events in JAKi vs TNFi. >270000 events. DECREASE in MACE ROR=0.87 [95%CI 0.80-0.95]. INCREASE in DVT: ROR=3.99 [3.15-5.04], PE: ROR=3.47 [2.90-4.13] @RheumNow #EULAR2022 OP0268 https://t.co/lUin7ciXWt https://t.co/Gr4Kvd8F7R

Survival of RA-ILD pts w/ lung 🫁 transplantation Retrospective single centre study *Mortality 36% *Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort) *Survival time comparable to other lung Tx cohorts #EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp

OP0285 Voclosoporin effective in #lupusNephritis from AURA-LV and AURORA1 to achieve EULAR/ERA nephritis targets (proteinuria < 0.7 mg/mg and pred < 7.5 mg/d) at 1 year @AuriniaPharma #EULAR2022 @rheumnow https://t.co/0GoCgP98F2

MACE in JAKi vs TNFi: did spontaneous reporting pharmacovigilance pick it? Vigibase: MACE (really MI) & VTE signals there before the scare Always chance regulatory warnings cause stimulated reporting but signal here was clear before RCT-driven alerts OP0268 #EULAR2022 @RheumNow https://t.co/hTJD1gMgyy

Video: Further Considerations of the ORAL Surveillance Study Further Considerations of ORAL Surveillance Study - this week there are new analyses and sub-analyses that further explain findings and who this data applies to. #EULAR2022 https://t.co/a2XKthtMbs https://t.co/kYNS1AesHT

Real world study of over 6500 patients from a French Health Insurance database by Pina Vegas et al showed higher persistence of IL17i than TNFi for PsA and PsO. IL17i had better persistence than IL12/23 for PsA and no difference for PsO over 3 years #EULAR2022 @RheumNow POS0075 https://t.co/hBI8tgb5Jb

WATCH: New 2022 ASAS/EULAR Recommendations on the Management of AxSpA Dr. Sophia Ramiro (Leiden University Medical Center) presents an overview of the new Spondyloarthritis treatment guidelines from ASAS/EULAR Task Force. #EULAR2022 https://t.co/AiCNQPm6KB https://t.co/kn4rmcbZrH

What is "backfill" on MRI? Answer: joint space lesions with a calcified matrix resembling new bone formation found in axSpA. #EULAR2022 POS0149 argues for a standardization of this nomenclature. @RheumNow https://t.co/ifrowQnRcn

To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog @RheumNow https://t.co/0cTep6MHLu